DALLAS-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.